Cannabis is not pharmacologically inert. Both THC and CBD are metabolized by — and inhibit — the cytochrome P450 enzyme system in the liver, the same enzyme system responsible for metabolizing approximately 60% of all pharmaceutical drugs.

This means cannabis can change how your medications work. It can make some drugs stronger (by slowing their breakdown), make others weaker (by competing for the same metabolic pathways), and in a few cases, create genuinely dangerous interactions.

Most physicians receive little to no training in cannabis pharmacology. Most budtenders have no pharmacological training at all. And most patients using cannabis alongside prescription medications are doing so without guidance from anyone who understands both systems.

This guide covers the most clinically significant interactions based on published pharmacokinetic and pharmacodynamic research.

How Cannabis Affects Drug Metabolism

The cytochrome P450 (CYP450) system is a family of liver enzymes that break down drugs, toxins, and other foreign substances in the body. Different drugs are metabolized by different CYP450 enzymes, and drug interactions occur when two substances compete for or inhibit the same enzyme.

CBD is a potent inhibitor of several CYP450 enzymes, particularly CYP3A4 and CYP2C19. At doses commonly used for therapeutic purposes (25–150 mg), CBD can significantly slow the metabolism of drugs processed by these enzymes, effectively increasing their concentration in the blood.

THC is metabolized primarily by CYP2C9 and CYP3A4 and is a less potent enzyme inhibitor than CBD, but still contributes to interactions at higher doses.

The clinical significance of these interactions depends on the specific medication, the cannabis dose, and whether the interaction increases the drug to toxic levels or reduces it below therapeutic levels.

Blood Thinners (Warfarin)

Risk level: High

Warfarin (Coumadin) has one of the narrowest therapeutic windows of any commonly prescribed drug — too little and you risk blood clots, too much and you risk uncontrolled bleeding. CBD inhibits CYP2C9, the primary enzyme that metabolizes warfarin, potentially increasing warfarin levels in the blood by 30–50%.

Multiple case reports document patients with previously stable INR (International Normalized Ratio — the measure of warfarin’s blood-thinning effect) experiencing dangerous INR spikes after starting CBD products. In one published case, a patient’s INR rose from a therapeutic 2.5 to a dangerous 8.0 after adding CBD oil.

What to do: If you take warfarin and use cannabis (especially CBD), inform your anticoagulation clinic. More frequent INR monitoring is essential. Dose adjustments may be needed. Do not start or stop CBD products without medical guidance.

Benzodiazepines

Risk level: Moderate to High

Benzodiazepines (diazepam, alprazolam, clonazepam, lorazepam) are metabolized by CYP3A4, which CBD inhibits. The combination can increase benzodiazepine blood levels, intensifying sedation, cognitive impairment, and respiratory depression risk.

Additionally, both cannabis and benzodiazepines produce sedation through different mechanisms — cannabis through CB1 receptors, benzodiazepines through GABA receptors. The additive sedative effect can be more intense than either substance alone, particularly in elderly patients.

What to do: If you use both, be aware that the sedative effect is amplified. Never increase your benzodiazepine dose to compensate for perceived tolerance — the cannabis interaction may already be increasing effective drug levels.

SSRIs and SNRIs (Antidepressants)

Risk level: Moderate

Common antidepressants including citalopram, escitalopram (Lexapro), sertraline (Zoloft), and fluoxetine (Prozac) are metabolized by CYP2C19 and CYP2D6. CBD inhibits CYP2C19 and may increase levels of these medications.

The more clinically relevant interaction may be pharmacodynamic rather than pharmacokinetic. Both CBD and SSRIs affect serotonin signaling — CBD activates 5-HT1A serotonin receptors while SSRIs increase serotonin availability at all receptor subtypes. In rare cases, this additive serotonergic effect could contribute to serotonin syndrome, a potentially dangerous condition characterized by agitation, confusion, rapid heart rate, and elevated body temperature.

What to do: If you are stable on an SSRI and add CBD, monitor for unusual symptoms including increased anxiety, agitation, tremor, or excessive sweating. These could indicate elevated serotonin signaling. Inform your prescribing physician.

Blood Pressure Medications

Risk level: Moderate

Cannabis (both THC and CBD) has independent blood-pressure-lowering effects. THC causes vasodilation (widening blood vessels), and CBD has been shown to reduce resting blood pressure by approximately 6 mmHg.

When combined with antihypertensive medications — ACE inhibitors, ARBs, calcium channel blockers, or beta-blockers — the additive blood pressure reduction can cause orthostatic hypotension (dizziness upon standing), lightheadedness, and in some cases, syncope (fainting).

This interaction is more pronounced in elderly patients, in patients taking multiple blood pressure medications, and when cannabis is consumed without food.

What to do: If you take blood pressure medication and use cannabis, monitor for dizziness when standing, especially after the first use. Stay hydrated. Consider reducing cannabis dose if lightheadedness occurs.

Opioid Pain Medications

Risk level: Moderate (but complex)

The cannabis-opioid interaction is pharmacologically complex because it has both beneficial and risky components.

Beneficial: Cannabis appears to enhance opioid analgesia through cannabinoid-opioid receptor crosstalk. Multiple studies have shown that patients using cannabis alongside opioids report equivalent pain relief at lower opioid doses. Some pain clinics actively use this interaction to facilitate opioid dose reduction.

Risky: Both cannabis and opioids cause sedation and respiratory depression (opioids more so). The combination increases these risks, particularly at higher doses of either substance. THC can also slow the metabolism of certain opioids through CYP3A4 inhibition, increasing their blood levels.

What to do: Cannabis-opioid combination should only be managed under medical supervision. The dose-reduction benefit is real but requires careful titration. Never increase opioid doses when using cannabis — the interaction may already be boosting effective opioid levels.

Immunosuppressants

Risk level: Moderate

Immunosuppressants like tacrolimus, cyclosporine, and sirolimus — used by organ transplant recipients and autoimmune patients — have narrow therapeutic windows and are metabolized by CYP3A4. CBD’s inhibition of this enzyme can increase immunosuppressant levels, potentially causing nephrotoxicity (kidney damage) and other adverse effects.

A 2019 case report documented a kidney transplant patient whose tacrolimus blood levels tripled after starting CBD, requiring emergency dose reduction.

What to do: Transplant recipients and patients on immunosuppressants should not start cannabis products without consulting their transplant team. Drug level monitoring is essential if cannabis is used.

Antiepileptic Drugs

Risk level: Moderate

The interaction between CBD and antiepileptic drugs is particularly well-studied because Epidiolex (pharmaceutical CBD) is FDA-approved for seizure disorders and is often used alongside existing anticonvulsants.

CBD significantly increases blood levels of clobazam (a benzodiazepine used for seizures) by inhibiting CYP2C19, the enzyme responsible for converting clobazam to its active metabolite. This interaction increases sedation and may require clobazam dose reduction.

CBD also interacts with valproic acid, increasing the risk of liver enzyme elevation (transaminitis). Liver function monitoring is recommended when CBD and valproate are used together.

What to do: Neurologists prescribing Epidiolex routinely manage these interactions. If you are using over-the-counter CBD products alongside anticonvulsants, inform your neurologist — the interactions are real and dose-dependent.

Diabetes Medications

Risk level: Low to Moderate

Cannabis (particularly THC) can affect blood sugar levels unpredictably. Acute THC use may increase blood glucose through cortisol-mediated stress responses, while chronic cannabis use is epidemiologically associated with lower fasting insulin and better insulin sensitivity.

For patients on insulin or sulfonylureas (medications that actively lower blood sugar), the concern is additive hypoglycemia — particularly if cannabis reduces appetite or causes nausea that prevents eating.

Metformin and cannabis do not have a significant pharmacokinetic interaction, but blood sugar monitoring remains advisable.

Statins

Risk level: Low to Moderate

Atorvastatin (Lipitor) and simvastatin are metabolized by CYP3A4. CBD’s inhibition of this enzyme could increase statin blood levels, potentially increasing the risk of myopathy (muscle pain and damage) — a known dose-dependent side effect of statins.

What to do: If you take statins and start using CBD, report any unusual muscle pain or weakness to your physician. Rosuvastatin and pravastatin are metabolized by different pathways and may be safer options.

General Principles

Several rules apply across all cannabis-drug interactions:

CBD is more problematic than THC for drug interactions because it is a more potent CYP450 enzyme inhibitor. This is counterintuitive — CBD is perceived as the “safe” cannabinoid — but its interaction profile is more complex than THC’s.

Dose matters. At low CBD doses (10–25 mg), enzyme inhibition is minimal. At therapeutic doses (50–150 mg), inhibition becomes clinically significant. At high doses (300+ mg), inhibition can be dramatic.

Timing matters. Taking cannabis and medications simultaneously maximizes the interaction. Separating doses by 2–4 hours can reduce (but not eliminate) the interaction.

Individual variation is enormous. CYP450 enzyme activity varies 10x between individuals based on genetics. Some people are “poor metabolizers” of certain enzymes and are more susceptible to interactions.

Tell your doctor. This is not a suggestion — it is a safety recommendation. Physicians cannot manage interactions they do not know about. Cannabis use should be part of your medication review, regardless of legal status.

The endocannabinoid system and the pharmaceutical metabolism system share the same liver. Ignoring that overlap does not make it disappear — it makes it dangerous.